Targeting the IL-4/IL-13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugs

International Journal of Cancer

Volumn 133, Issue 8, 2013, Pages 1945-1954

  Natoli, Antonino ^a   Lüpertz, Regine ^a   Merz, Christian ^b   Müller, Wolfgang W ^a   Köhler, Rebecca ^a   Krammer, Peter H ^a   Li Weber, Min ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Apogenix GmbHINF584   (Germany)

Author keywords

apoptosis; Bcl xL; cytokine; Hodgkin lymphoma; IL 13; IL 4; STAT6

Indexed keywords

ANTINEOPLASTIC AGENT; APG 201; APG 598; CYTOKINE RECEPTOR ANTAGONIST; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; INTERLEUKIN 13; INTERLEUKIN 4; MITOMYCIN; PACLITAXEL; PROTEIN BCL XL; STAT6 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG SENSITIZATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE;

APOPTOSIS; BCL-XL; CYTOKINE; HODGKIN LYMPHOMA; IL-13; IL-4; STAT6;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-X PROTEIN; CELL LINE, TUMOR; DOXORUBICIN; ENZYME ACTIVATION; ETOPOSIDE; FLUOROURACIL; HODGKIN DISEASE; HUMANS; INTERLEUKIN-13; INTERLEUKIN-4; MITOMYCIN; PACLITAXEL; PROMOTER REGIONS, GENETIC; REED-STERNBERG CELLS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT6 TRANSCRIPTION FACTOR;

EID: 84881555435     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28189     Document Type: Article

References (41)

1. Diehl V, Thomas RK, Re D,. Part II: Hodgkin's lymphoma-diagnosis and treatment. Lancet Oncol 2004; 5: 19-26.
2. Re D, Thomas RK, Behringer K, et al. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood 2005; 105: 4553-60.
3. Böll B, Borchmann P, Diehl V,. Emerging drugs for Hodgkin's lymphoma. Expert Opin Emerg Drugs 2010; 15: 585-95.
4. Yu H, Pardoll D, Jove R,. STATs in cancer inflammation and immunity: a leading role for STAT3 Nat Rev Cancer 2009; 9: 798-809.
5. Skinnider BF, Elia AJ, Gascoyne RD, et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma Blood 2002; 99: 618-26.
6. Cochet O, Frelin C, Peyron JF, et al. Constitutive activation of STAT proteins in the HDLM-2 and L540 Hodgkin lymphoma-derived cell lines supports cell survival. Cell Signal 2006; 18: 449-55.
7. Buglio D, Georgakis GV, Hanabuchi S, et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008; 112: 1424-33.
8. Bruns HA, Kaplan MH, The role of constitutively active Stat6 in leukemia and lymphoma. Crit Rev Oncol Hematol 2006; 57: 245-53.
9. Weniger MA, Melzner I, Menz CK, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 2006; 25: 2679-84.
10. Mottok A, Renné C, Willenbrock K, et al. Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood 2007; 110: 3387-90.
11. Kapp U, Yeh WC, Patterson B, et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 1999; 189: 1939-46.
12. Trieu Y, Wen XY, Skinnider BF, et al. Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivo. Cancer Res 2004; 64: 3271-275.
13. Holtick U, Vockerodt M, Pinkert D, et al. STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis. Leukemia 2005; 19: 936-44.
14. Baus D, Pfitzner E,. Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells. Int J Cancer 2006; 118: 1404-13.
15. Diaz T, Navarro A, Ferrer G, et al. Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis. PLoS One 2011; 6: e18856.
16. Skinnider BF, Mak TW,. The role of cytokines in classical Hodgkin lymphoma Blood 2002; 99: 4283-297.
17. Steidl C, Connors JM, Gascoyne RD,. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the Importance of the microenvironment J Clin Oncol 2011; 29: 1812-26.
18. Poppema S, Bhan AK, Reinherz EL, et al. In situ immunologic characterization of cellular constituents in lymph nodes and spleens involved by Hodgkin's disease. Blood 1982; 59: 226-32.
19. Ma Y, Visser L, Blokzijl T, et al. T-cell population in classical Hodgkin's lymphoma displays a distinctive regulatory T-cell profile. Lab Invest 2008; 88: 482-90.
20. Schmitz R, Stanelle J, Hansmann ML, et al. Pathogenesis of Classical and Lymphocyte-Predominant Hodgkin Lymphoma. Annu Rev Pathol 2009; 4: 151-74.
21. Küppers R,. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009; 9: 15-27.
22. Kawakami M, Kawakami K, Kioi M, et al. Hodgkin lymphoma therapy with interleukin-4 receptor-directed cytotoxin in an infiltrating animal model. Blood 2005; 105: 3707-13.
23. Mainou-Fowler T, Proctor SJ, Taylor PRA,. Interleukin 4 production by peripheral blood lymphocytes in patients with classical Hodgkin lymphoma. Leukemia Res 2004; 28: 159-66.
24. Wills-Karp M, Finkelman FD,. Untangling the complex web of IL-4- and IL-13-mediated signaling pathways. Sci Signal 2008; 1: pe55.
25. Newcom SR, Ansari AA, Gu L,. Interleukin-4 is an autocrine growth factor secreted by the L-428 Reed- Sternberg cell Blood 1992; 79: 191-97.
26. Tony HP, Shen BJ, Reusch P, et al. Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin-13-dependent responses in T-cells and B-cells with high efficiency. Eur J Biochem 1994: 225; 659-65.
27. Nicoletti I, Migliorati G, Pagliacci MC, et al. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 199; 139: 271-79.
28. Skinnider BF, Kapp U, Mak TW,. Interleukin 13: a growth factor in Hodgkin lymphoma. Int Arch Allergy Immunol 2001; 126: 267-76.
29. Wurster AL, Rodgers VL, White MF, et al. Interleukin-4-mediated protection of primary B cells from apoptosis through Stat6-dependent up-regulation of Bcl-xL. J Biol Chem 2002; 277: 27169-75.
30. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478-84.
31. Kube D, Holtick U, Vockerodt M, et al. STAT3 is constitutively activated in Hodgkin cell lines. Blood 2001; 98: 762-70.
32. Skinnider BF, Elia AJ, Gascoyne RD, et al. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2001: 97: 250-55.
33. Skinnider BF, Kapp U, Mak TW,. The role of interleukin 13 in classical Hodgkin lymphoma. Leuk Lymphoma 2002; 43: 1203-10.
34. Pileri SA, Ascani S, Leoncini L, et al. Hodgkin's lymphoma: the pathologist's viewpoint. J Clin Pathol 2002; 55: 162-76.
35. Aldinucci D, Lorenzon D, Cattaruzza L, et al. Expression of CCR5 receptors on Reed Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Intl J Cancer 2008; 122: 769-76.
36. Tan TT, Coussens LM,. Humoral immunity, inflammation and cancer. Current Opin Immunol 2007; 19: 209-16.
37. Clerici M, Ferrario E, Trabattoni D, et al. Multiple defects of T helper cell function in newly diagnosed patients with Hodgkin's disease. Eu J Cancer 1994; 30: 1464-70.
38. Adams JM, Cory S,. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322-6.
39. Xerrp L, Hassoun J, Devilard E, et al. BCL-X and the apoptotic machinery of lymphoma cells. Leuk Lymphoma 1998; 28: 451-8.
40. Joos S, Granzow M, Holtgreve-Grez H, et al. Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. Int J Cancer 2003; 103: 489-95.
41. Kluiver J, Kok K, Pfeil I, et al. Global correlation of genome and transcriptome changes in classical Hodgkin lymphoma. Hematol Oncol 2007; 25: 21-9.